Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026)
Vireo Growth's (VREOF) quarterly Cash & Equivalents came in at $122.4 million in Q1 2026, up 42.0% year-on-year from $86.2 million in Q1 2025, and little changed quarter-over-quarter from $122.5 million in Q4 2025.
Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Cash & Equivalents across 7 years of filings, most recently posting $122.4 million for Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $122.4 million, up 42.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.4 million (up 42.0% YoY), and the FY2025 annual result was $122.5 million, up 33.73% from the prior year.
- Cash & Equivalents came in at $122.4 million for Q1 2026 at Vireo Growth, roughly flat from $122.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $122.5 million in Q4 2025 to a low of $7.3 million in Q3 2024.
- The 5-year median for Cash & Equivalents is $16.0 million (2023), against an average of $46.5 million.
- Across the five-year window, Cash & Equivalents sank 78.79% in 2022 and surged 1514.58% in 2025, its largest moves.
- Vireo Growth's Cash & Equivalents stood at $15.1 million in 2022, then gained by 5.38% to $16.0 million in 2023, then jumped by 473.77% to $91.6 million in 2024, then jumped by 33.73% to $122.5 million in 2025, then retreated by 0.08% to $122.4 million in 2026.
- The last three Cash & Equivalents figures came in at $122.4 million (Q1 2026), $122.5 million (Q4 2025), and $117.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 1.28 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 40.42 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 266.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 351.55 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 222.27 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 498.58 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 122.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122.40 Mn |
| Dec 31, 2025 | 122.50 Mn |
| Sep 30, 2025 | 117.54 Mn |
| Jun 30, 2025 | 106.19 Mn |
| Mar 31, 2025 | 86.20 Mn |
| Dec 31, 2024 | 91.60 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 21.84 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 11.78 Mn |
| Jun 30, 2021 | 20.83 Mn |